Holen Sie sich die Stockscreener-App
48.81
2.40%
-1.20
Handel nachbörslich:
48.55
-0.26
-0.53%
Scholar Rock Holding Corp Aktie (SRRK) Neueste Nachrichten
Mohammed Qatanani (NASDAQ: SRRK) files Form 144 to sell 23,408 shares via option exercise - stocktitan.net
Scholar Rock to rally around 18%? Here are 10 top analyst forecasts for Wednesday - MSN
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
SG Americas Securities LLC Has $3.72 Million Stock Position in Scholar Rock Holding Corporation $SRRK - marketbeat.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Jefferies raises Scholar Rock stock price target on BLA resubmission - Investing.com UK
Jefferies raises Scholar Rock stock price target on BLA resubmission By Investing.com - Investing.com India
SRRK Stock: Wedbush Raises Price Target to $58, Maintains Outper - GuruFocus
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug - Yahoo Finance
Wedbush Forecasts Strong Price Appreciation for Scholar Rock (NASDAQ:SRRK) Stock - marketbeat.com
Scholar Rock (NASDAQ:SRRK) Sets New 12-Month HighShould You Buy? - marketbeat.com
SRRK Technical Analysis | Trend, Signals & Chart Patterns | SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) - ChartMill
Scholar Rock Resubmits Apitegromab BLA for SMA, Adds Second Fill-Finish Site; FDA Decision Eyed by Sept. - marketbeat.com
Why Scholar Rock Holding (SRRK) Is Up 16.2% After Apitegromab BLA Resubmission With FDA-Aligned Manufacturing - simplywall.st
Scholar Rock Holding Corp stock hits 52-week high at 49.98 USD - Investing.com Australia
Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright - TipRanks
Scholar Rock Resubmits Apitegromab BLA to FDA for Spinal Muscular Atrophy Treatment, Anticipates Approval in Late 2026 123 - Minichart
Scholar Rock (SRRK) Resubmits Key Application, Stock Climbs - GuruFocus
Scholar Rock (SRRK) Stock Surges 15.5% - GuruFocus
Scholar Rock (SRRK) Shares Rise Following BLA Resubmission - GuruFocus
Scholar Rock (NASDAQ:SRRK) Shares Gap UpHere's Why - marketbeat.com
Scholar Rock (SRRK) Resubmits BLA for Apitegromab Targeting SMA - GuruFocus
Scholar Rock stock surges on FDA resubmission for SMA drug By Investing.com - Investing.com UK
Scholar Rock (SRRK) resubmits apitegromab BLA with FDA, eyes Sept 2026 decision - Stock Titan
Biopharmaceutical company Scholar Rock Holding Corp (SRRK) recently announced that regarding the resubmission of its Biologics License Application (BLA), the company expects the U.S. Food and Drug Administration (FDA) to accept the filing within 30 d - Bitget
Scholar Rock resubmits apitegromab application to FDA By Investing.com - Investing.com UK
Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) - Yahoo Finance
A Look At Scholar Rock Holding (SRRK) Valuation As Growth Expectations Face Mixed Share Price Signals - Yahoo Finance
Is Scholar Rock Holding (SRRK) Still Attractive After Recent Share Price Pullback? - simplywall.st
Scholar Rock: From Manufacturing Hurdle To Commercial Muscle, Maintaining Buy Rating (NASDAQ:SRRK) - Seeking Alpha
Vanguard disaggregates holdings, reports 0 shares for Scholar Rock (SRRK) - Stock Titan
E. Ohman J or Asset Management AB Has $721,000 Stake in Scholar Rock Holding Corporation $SRRK - MarketBeat
JPMorgan Chase & Co. Buys 440,401 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Analysts - marketbeat.com
SRRK PE Ratio & Valuation, Is SRRK Overvalued - Intellectia AI
Stocks flashing renewed technical strength: Scholar Rock Holding - MSN
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
Cantor Fitzgerald reiterates Scholar Rock stock rating on rival setback By Investing.com - Investing.com Australia
Scholar Rock Holding Surges 10.6% in Intraday Trade – What’s Behind the Volatility? - Bitget
BMO reiterates Scholar Rock stock rating on rival drug discontinuation By Investing.com - Investing.com South Africa
Truist reiterates Buy on Scholar Rock stock after Roche halts rival drug By Investing.com - Investing.com South Africa
Truist reiterates Buy on Scholar Rock stock after Roche halts rival drug - Investing.com
BMO reiterates Scholar Rock stock rating on rival drug discontinuation - Investing.com
Scholar Rock (SRRK) Shares Surge Following Analyst Note - GuruFocus
Cantor Fitzgerald reiterates Scholar Rock stock rating on rival setback - Investing.com
Scholar Rock (NASDAQ:SRRK) Trading Up 7.1%Here's Why - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):